DRUG-INTERACTIONS WITH QUINOLONES

被引:63
作者
JANKNEGT, R
机构
[1] Department of Clinical Pharmacology, Toxicology, Maasland Hospital, Sittard, 6130
关键词
D O I
10.1093/jac/26.suppl_D.7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The pharmacodynamic and phannacokinetic drug interactions and pharmaceutica compatibilities of fluoroquinolones are reviewed. Incompatibilities are observed between quinolones and penicillins such as flucloxacillin and amoxicillin and with clindamycin when mixed in an administration set. Fluoroquinolones, especially cnoxacin, and to a lesser extent ciprofloxacin and pefloxacin, inhibit the metabolic clearance of theophyllinc and caffeine. It is advisable to use non-interacting quinolones such as ofloxacin or norfloxacin or to measure theophylline levels and reduce caffeine intake where appropriate. A potential interaction with midazolam needs further study. The absorption of fluoroquinolones is markedly reduced by antacids, calcium carbonate, ferrous sulphate and sucralfate. Although quantitative differences between fluoroquinolones exist, these combinations should be avoided whenever possible. Cimetidine reduces the metabolic clearance of pefloxacin. More studies are needed on the possible reduction of absorption of fluoroquinolones by opiates. Several case reports of a pharmacodynamic interaction between fluoroquinolones and cyclosporin or oral anticoagulants exist. No pharmacokinetic interaction has been observed and more, controlled studies are needed to assess the significance of the pharmacodynamic interaction. A high incidence of convulsions has been observed in patients receiving the combination enoxacin and fenbufen, an NSAID. A synergistic inhibitory effect of fluoroquinolones and several NSAIDs has been observed on the binding of the neurotransmitter GABA. Although the relevance of this interaction is probably not great, except with fenbufen, a possible epileptogenic effect of the combination cannot be excluded. © 1990 The British Society for Antimicrobial Chemotherapy.
引用
收藏
页码:7 / 29
页数:23
相关论文
共 98 条
[1]   STRUCTURE-EPILEPTOGENICITY RELATIONSHIP OF QUINOLONES WITH SPECIAL REFERENCE TO THEIR INTERACTION WITH GAMMA-AMINOBUTYRIC ACID RECEPTOR-SITES [J].
AKAHANE, K ;
SEKIGUCHI, M ;
UNE, T ;
OSADA, Y .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (10) :1704-1708
[2]   SYNERGISTIC NEPHROTOXICITY DUE TO CIPROFLOXACIN AND CYCLOSPORINE [J].
AVENT, CK ;
KRINSKY, D ;
KIRKLIN, JK ;
BOURGE, RC ;
FIGG, WD .
AMERICAN JOURNAL OF MEDICINE, 1988, 85 (03) :452-453
[3]   ENOXACIN - A POTENT INHIBITOR OF THEOPHYLLINE METABOLISM [J].
BECKMANN, J ;
ELSASSER, W ;
GUNDERTREMY, U ;
HERTRAMPF, R .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 33 (03) :227-230
[4]   EFFECT OF NORFLOXACIN ON THEOPHYLLINE PHARMACOKINETICS AT STEADY-STATE [J].
BOWLES, SK ;
POPOVSKI, Z ;
RYBAK, MJ ;
BECKMAN, HB ;
EDWARDS, DJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (04) :510-512
[5]  
BRFOUWERS JR, 1989, PHARM WEEKBLAD SC SE, V11, P13
[6]  
CHRIST W, 1989, REV INFECT DIS, V11, pS1393
[7]  
DAVIES BI, 1989, REV INFECT DIS, V11, pS1083
[8]  
DAVIS R L, 1988, Drug Interactions Newsletter, V8, P27
[9]   EFFECT OF NORFLOXACIN ON THEOPHYLLINE METABOLISM [J].
DAVIS, RL ;
KELLY, HW ;
QUENZER, RW ;
STANDEFER, J ;
STEINBERG, B ;
GALLEGOS, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (02) :212-214
[10]  
DEPPERMANN KM, 1989, AM J MED S, V87, P46